Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | HPGDS | O60760 | 2/20 | 0.33 |
| ▸ | SYK | P43405 | 1/20 | 0.31 |
| ▸ | ABL1 | P00519 | 1/20 | 0.31 |
| ▸ | BCR | P11274 | 1/20 | 0.31 |
| ▸ | ADRA2A | P08913 | 2/20 | 0.31 |
| ▸ | ADRA1A | P35348 | 2/20 | 0.31 |
| ▸ | ADRA1D | P25100 | 1/20 | 0.31 |
| ▸ | MGLL | Q99685 | 1/20 | 0.31 |
| ▸ | TOP1 | P11387 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL19780736 | 0.97 | HPGDS (0.34) | HPGDSSYKABL1BCRADRA2A | |
| SCHEMBL21480908 | 0.95 | HPGDS (0.35) | HPGDSADRA2AADRA1AADRA1D | |
| SCHEMBL21477360 | 0.88 | FFAR2 (0.35) | HPGDS | |
| SCHEMBL21721913 | 0.87 | ABL1 (0.34) | SYKABL1BCRADRA2AADRA1A | |
| SCHEMBL21125634 | 0.86 | ALOX5AP (0.34) | ABL1BCRADRA2AADRA1AADRA1D | |
| SCHEMBL21480904 | 0.85 | ABL1 (0.35) | ABL1BCRADRA2AADRA1AADRA1D | |
| SCHEMBL21477352 | 0.84 | LDHA (0.35) | ABL1BCRADRA2AADRA1AADRA1D | |
| SCHEMBL21480913 | 0.84 | LDHA (0.35) | ABL1BCRADRA2AADRA1AADRA1D | |
| SCHEMBL19781093 | 0.83 | — | — | |
| SCHEMBL19833583 | 0.82 | HPGDS (0.35) | HPGDSSYK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230322826-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-10-12 | — | — | US | disclosed |
| US-20230322826-A1 | METAL COMPLEXES | UDC IRELAND LIMITED (IE) | 2023-10-12 | — | — | US | disclosed |
| US-11713332-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2023-08-01 | — | — | US | disclosed |
| US-11713332-B2 | Metal complexes | MERCK PATENT GMBH (DE) | 2023-08-01 | — | — | US | disclosed |
| EP-3484868-B1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2020-11-25 | — | — | EP | disclosed |
| US-20190315787-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2019-10-17 | — | — | US | disclosed |
| WO-2018011186-A1 | METAL COMPLEXES | MERCK PATENT GMBH (DE) | 2018-01-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190315787-A1 | METAL COMPLEXES | AP1M1, SOD1, AP3M1 | HPGDS 4680/4885SYK 4588/4885ABL1 2641/4885 |
| US-11713332-B2 | Metal complexes | AP1M1, SOD1, AP3M1 | HPGDS 4680/4885SYK 4588/4885ABL1 2641/4885 |
| US-20230322826-A1 | METAL COMPLEXES | AP1M1, SOD1, AP3M1 | HPGDS 4680/4885SYK 4588/4885ABL1 2641/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.